* patient with severe pneumonia confirmed by imaging test (conventional radiology or computerized axial tomography (ct)) with ambient air oxygen saturation (sato2) ≤94%. * another acute active infection other than that produced by sars-cov-2. * chronic renal failure (estimated glomerular filtration ≤ 30 ml / min / 1.73 m2 or receiving renal replacement therapy in any of its modalities). * known hiv infection. unless the patient has\> 500 cd4 + / mm3 and an undetectable viral load for more than 6 months. * active co-infection with known hepatitis b or c viruses. * cirrhosis, portal hypertension and / or hypersplenism of any etiology. * past or current neoplasms subsidiary to treatment with steroids, immunomodulators or chemotherapy * laboratory abnormalities. * concomitant use of drugs with major pharmacological interactions with the study drugs, according to the respective technical specifications of the products. * pregnancy.

* patient with severe pneumonia confirmed by imaging test (conventional radiology or computerized axial tomography (ct)) with ambient air oxygen saturation (sato2) ≤94%. * another acute active infection other than that produced by sars-cov-2. * chronic renal failure (estimated glomerular filtration ≤ 30 ml / min / 1.73 m2 or receiving renal replacement therapy in any of its modalities). * known hiv infection. unless the patient has\> 500 cd4 + / mm3 and an undetectable viral load for more than 6 months. * active co-infection with known hepatitis b or c viruses. * cirrhosis, portal hypertension and / or hypersplenism of any etiology. * past or current neoplasms subsidiary to treatment with steroids, immunomodulators or chemotherapy * laboratory abnormalities. * concomitant use of drugs with major pharmacological interactions with the study drugs, according to the respective technical specifications of the products. * pregnancy.

- patient with severe pneumonia confirmed by imaging test (conventional radiology or computerized axial tomography (ct)) with ambient air oxygen saturation (sato2) ≤94%. - another acute active infection other than that produced by sars-cov-2. - chronic renal failure (estimated glomerular filtration ≤ 30 ml / min / 1.73 m2 or receiving renal replacement therapy in any of its modalities). - known hiv infection. unless the patient has> 500 cd4 + / mm3 and an undetectable viral load for more than 6 months. - active co-infection with known hepatitis b or c viruses. - cirrhosis, portal hypertension and / or hypersplenism of any etiology. - past or current neoplasms subsidiary to treatment with steroids, immunomodulators or chemotherapy - laboratory abnormalities. - concomitant use of drugs with major pharmacological interactions with the study drugs, according to the respective technical specifications of the products. - pregnancy.

- patient with severe pneumonia confirmed by imaging test (conventional radiology or computerized axial tomography (ct)) with ambient air oxygen saturation (sato2) ≤94%. - another acute active infection other than that produced by sars-cov-2. - chronic renal failure (estimated glomerular filtration ≤ 30 ml / min / 1.73 m2 or receiving renal replacement therapy in any of its modalities). - known hiv infection. unless the patient has> 500 cd4 + / mm3 and an undetectable viral load for more than 6 months. - active co-infection with known hepatitis b or c viruses. - cirrhosis, portal hypertension and / or hypersplenism of any etiology. - past or current neoplasms subsidiary to treatment with steroids, immunomodulators or chemotherapy - laboratory abnormalities. - concomitant use of drugs with major pharmacological interactions with the study drugs, according to the respective technical specifications of the products. - pregnancy.

- patient with severe pneumonia confirmed by imaging test (conventional radiology or computerized axial tomography (ct)) with ambient air oxygen saturation (sato2) ≤94%. - another acute active infection other than that produced by sars-cov-2. - chronic renal failure (estimated glomerular filtration ≤ 30 ml / min / 1.73 m2 or receiving renal replacement therapy in any of its modalities). - known hiv infection. unless the patient has> 500 cd4 + / mm3 and an undetectable viral load for more than 6 months. - active co-infection with known hepatitis b or c viruses. - cirrhosis, portal hypertension and / or hypersplenism of any etiology. - past or current neoplasms subsidiary to treatment with steroids, immunomodulators or chemotherapy - grade 3 or 4 laboratory abnormalities. - concomitant use of drugs with major pharmacological interactions with the study drugs, according to the respective technical specifications of the products. - estimated creatinine clearance <50ml / min. - pregnancy.

- patient with severe pneumonia confirmed by imaging test (conventional radiology or computerized axial tomography (ct)) with ambient air oxygen saturation (sato2) ≤94%. - another acute active infection other than that produced by sars-cov-2. - chronic renal failure (estimated glomerular filtration ≤ 30 ml / min / 1.73 m2 or receiving renal replacement therapy in any of its modalities). - known hiv infection. unless the patient has> 500 cd4 + / mm3 and an undetectable viral load for more than 6 months. - active co-infection with known hepatitis b or c viruses. - cirrhosis, portal hypertension and / or hypersplenism of any etiology. - past or current neoplasms subsidiary to treatment with steroids, immunomodulators or chemotherapy - grade 3 or 4 laboratory abnormalities. - concomitant use of drugs with major pharmacological interactions with the study drugs, according to the respective technical specifications of the products. - estimated creatinine clearance <50ml / min. - pregnancy.